Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; Analysis according to St Gallen consensus and intrinsic subtypes

Journal of Surgical Oncology

Volumn 103, Issue 3, 2011, Pages 207-211

  Jung, So Youn ^a   Jeong, Junsoo ^a   Shin, Seung Ho ^a   Kwon, Youngmee ^a   Kim, Eun A ^a   Ko, Kyoung Lan ^a   Shin, Kyung Hwan ^a   Ro, Jungsil ^a   Lee, Keun Seok ^a   Park, In Hae ^a   Lee, Seeyoun ^a   Kim, Seok Won ^a   Kang, Han Sung ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE NEGATIVE BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952031545     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21819     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
2. Boyages J, Taylor R, Chua B, et al.: A risk index for early nodenegative breast cancer. Br J Surg 2006;93:564-571.
3. Goldhirsch A, Ingle JN, Gelber RD, et al.: Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20: 1319-1329.
4. Goldhirsch A,Wood WC, Gelber RD, et al.: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144.
5. Sorlie T, Tibshirani R, Parker J, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423. (Pubitemid 36842560)
6. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
7. Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
8. Chen X,Ko LJ, Jayaraman L, et al.: p53 levels, functional domains, andDNAdamage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996;10:2438-2451. (Pubitemid 26341879)
9. Alsner J,Yilmaz M, Guldberg P, et al.: Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000;6:3923-3931.
10. Pharoah PD, Day NE, Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 1999;80:1968-1973 . (Pubitemid 29391282)
11. Linjawi A, Kontogiannea M, Halwani F, et al.: Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. JAm Coll Surg 2004;198:83-90. (Pubitemid 38201092)
12. Silvestrini R, Benini E, Veneroni S, et al.: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996;14:1604-1610. (Pubitemid 26134219)
13. Korkolis DP, Tsoli E, Fouskakis D, et al.: Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res 2004;24:2061-2068.
14. Barbareschi M, Caffo O, Veronese S, et al.: Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up. Hum Pathol 1996;27:1149-1155. (Pubitemid 26374933)
15. Olivier M, Langerod A, Carrieri P, et al.: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-1167. (Pubitemid 43342504)
16. Alsner J, Jensen V, Kyndi M, et al.: A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008;47:600-607. (Pubitemid 351878460)
17. Soussi T: p53 alterations in human cancer: More questions than answers. Oncogene 2007;26:2145-2156.
18. Kim HS, Yom CK, Kim HJ, et al.: Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res Treat 2010;121:777-788.
19. Knoop AS, Bentzen SM, Nielsen MM, et al.: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376-3384. (Pubitemid 32642190)
20. Berry DA, Muss HB, Thor AD, et al.: HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471-3479.
21. Berns EM, Klijn JG, van Putten WL, et al.: p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 1998;16:121-127. (Pubitemid 28041588)
22. Yamashita H, Nishio M, Toyama T, et al.: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004;6:R24-30.
23. Chae BJ, Bae JS, Lee A, et al.: p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009;39:217-224.